Phio Pharmaceuticals Corp Stock Performance
| PHIO Stock | USD 2.51 0.03 1.18% |
On a scale of 0 to 100, Phio Pharmaceuticals holds a performance score of 5. The company holds a Beta of 0.49, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Phio Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Phio Pharmaceuticals is expected to be smaller as well. Please check Phio Pharmaceuticals' downside variance, and the relationship between the sortino ratio and accumulation distribution , to make a quick decision on whether Phio Pharmaceuticals' historical price patterns will revert.
Risk-Adjusted Performance
Modest
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Phio Pharmaceuticals Corp are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of very weak forward indicators, Phio Pharmaceuticals displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (1.18) | Five Day Return 3.72 | Year To Date Return 32.11 | Ten Year Return (100.00) | All Time Return (99.20) |
Last Split Factor 1:9 | Dividend Date 2020-01-15 | Last Split Date 2024-07-05 |
1 | Disposition of 4011 shares by Caitlin Kontulis of Phio Pharmaceuticals at 0.821 subject to Rule 16b-3 | 05/16/2025 |
2 | Acquisition by Ferrara Robert L of 2500 shares of Phio Pharmaceuticals at 1.82 subject to Rule 16b-3 | 05/20/2025 |
3 | Acquisition by Robert Bitterman of 3000 shares of Phio Pharmaceuticals at 1.77 subject to Rule 16b-3 | 05/21/2025 |
4 | Acquisition by Robert Bitterman of 1200 shares of Phio Pharmaceuticals at 1.7799 subject to Rule 16b-3 | 05/22/2025 |
5 | Phio Pharma Receives Buy Rating and 14 Price Target from HC Wainwright PHIO Stock News | 06/05/2025 |
6 | Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio | 06/06/2025 |
7 | Acquisition by Robert Bitterman of 1500 shares of Phio Pharmaceuticals at 2.75 subject to Rule 16b-3 | 06/09/2025 |
8 | Acquisition by Ferrara Robert L of 2500 shares of Phio Pharmaceuticals at 2.4199 subject to Rule 16b-3 | 06/10/2025 |
9 | Insider Trading | 06/17/2025 |
10 | Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation... | 06/25/2025 |
11 | Phio Pharmaceuticals Announces 2025 Annual Meeting Details - TipRanks | 07/07/2025 |
12 | Acquisition by Lockshin Curtis of 10000 shares of Phio Pharmaceuticals subject to Rule 16b-3 | 07/15/2025 |
13 | Phio Pharmaceuticals Corp. Stock Analysis and Forecast - High-impact stock picks - jammulinksnews.com | 07/18/2025 |
14 | What analysts say about Phio Pharmaceuticals Corp. stock - Exceptional stock performance - jammulinksnews.com | 07/22/2025 |
| Begin Period Cash Flow | 8.5 M | |
| Total Cashflows From Investing Activities | 8000.00 |
Phio Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 214.00 in Phio Pharmaceuticals Corp on April 26, 2025 and sell it today you would earn a total of 37.00 from holding Phio Pharmaceuticals Corp or generate 17.29% return on investment over 90 days. Phio Pharmaceuticals Corp is currently generating 0.4501% in daily expected returns and assumes 6.3363% risk (volatility on return distribution) over the 90 days horizon. In different words, 56% of stocks are less volatile than Phio, and 91% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Phio Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Phio Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Phio Pharmaceuticals Corp, and traders can use it to determine the average amount a Phio Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.071
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | PHIO | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.34 actual daily | 56 56% of assets are less volatile |
Expected Return
| 0.45 actual daily | 9 91% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average Phio Pharmaceuticals is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Phio Pharmaceuticals by adding it to a well-diversified portfolio.
Phio Pharmaceuticals Fundamentals Growth
Phio Stock prices reflect investors' perceptions of the future prospects and financial health of Phio Pharmaceuticals, and Phio Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Phio Stock performance.
| Return On Equity | -0.76 | ||||
| Return On Asset | -0.43 | ||||
| Current Valuation | 3.73 M | ||||
| Shares Outstanding | 4.8 M | ||||
| Price To Earning | (0.80) X | ||||
| Price To Book | 1.00 X | ||||
| Price To Sales | 48.01 X | ||||
| Gross Profit | (3.67 M) | ||||
| EBITDA | (7.12 M) | ||||
| Net Income | (7.15 M) | ||||
| Cash And Equivalents | 18.02 M | ||||
| Cash Per Share | 1.32 X | ||||
| Total Debt | 1.01 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 6.48 X | ||||
| Book Value Per Share | 2.55 X | ||||
| Cash Flow From Operations | (7.11 M) | ||||
| Earnings Per Share | (9.02) X | ||||
| Market Capitalization | 12.35 M | ||||
| Total Asset | 5.74 M | ||||
| Retained Earnings | (146.36 M) | ||||
| Working Capital | 4.72 M | ||||
| Current Asset | 9.23 M | ||||
| Current Liabilities | 2.17 M | ||||
About Phio Pharmaceuticals Performance
By examining Phio Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Phio Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Phio Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.25) | (1.31) | |
| Return On Capital Employed | (1.56) | (1.49) | |
| Return On Assets | (1.25) | (1.31) | |
| Return On Equity | (1.51) | (1.44) |
Things to note about Phio Pharmaceuticals Corp performance evaluation
Checking the ongoing alerts about Phio Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Phio Pharmaceuticals Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Phio Pharmaceuticals had very high historical volatility over the last 90 days | |
| Phio Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (7.15 M) with loss before overhead, payroll, taxes, and interest of (3.67 M). | |
| Phio Pharmaceuticals Corp currently holds about 18.02 M in cash with (7.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.32. | |
| Latest headline from news.google.com: What analysts say about Phio Pharmaceuticals Corp. stock - Exceptional stock performance - jammulinksnews.com |
- Analyzing Phio Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Phio Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Phio Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Phio Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Phio Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Phio Pharmaceuticals' stock. These opinions can provide insight into Phio Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Phio Pharmaceuticals Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Phio Pharmaceuticals. If investors know Phio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Phio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Phio Pharmaceuticals Corp is measured differently than its book value, which is the value of Phio that is recorded on the company's balance sheet. Investors also form their own opinion of Phio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Phio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Phio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Phio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Phio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Phio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Phio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.